An additional six months of data from a late-stage trial of Takeda Pharmaceutica...
CHICAGO - An additional six months of data from a late-stage trial of Takeda Pharmaceutical Co’s experimental dengue vaccine again showed it failed to protect against one of the four types of the virus in an important patient group, researchers said on Saturday.
Initial results, published this month in the New England Journal of Medicine, showed the vaccine succeeded overall but failed to protect against dengue 3 in children and teens who had never previously been exposed to the mosquito-borne disease. That appeared to have happened with Sanofi’s Dengvaxia, the world’s first dengue vaccine. Two years after Dengvaxia was licensed in 2015, the company disclosed that it increased the risk of severe disease in children not previously infected, a group known as seronegatives.
The vaccine proved 90.4% effective at preventing hospitalized dengue and 85.9% effective at preventing hemorrhagic fever.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Takeda says cancer drug Alunbrig shows longer benefit vs. crizotinibJapan's biggest drugmaker, Takeda Pharmaceutical Co Ltd, said long-term dat...
続きを読む »
Beck Says He is No Longer a Scientologist: ‘I Don’t Have Any Connection With It’Beck Says He is No Longer a Scientologist: 'I Don't Have Any Connection With It'(via JustJared)
続きを読む »
Prince Andrew is Reportedly No Longer Welcome in Buckingham PalacePrince Andrew was reportedly kicked out of Buckingham Palace.
続きを読む »
Laemmle Theatres Arthouse Chain No Longer Seeking BuyerLos Angeles-based arthouse chain Laemmle Theatres has stopped seeking a buyer, four months after putting itself on the sales block amid slow sales. Greg Laemmle, president of the 81-year-old exhibi…
続きを読む »